Print Friendly
Beyond the Survey: Epidemiology For the 21st Century
Myrna Weissman, PhD
Professor of Epidemiology and Psychiatry, Columbia University
This interview was conducted by Peter Cook on June 29, 2006.
After graduate school
at Yale University, Dr. Myrna Weissman was part of the first large-scale
epidemiological community surveys of psychiatric disorders in the US. “At that time,” she says, “there were epidemiologic surveys being done on cancer, heart
disease, and other physiological ailments which I had learned about in school.
Psychiatry, which was my interest, was not at the table. The surveys in
psychiatry focused on stress or overall wellness. None in the U.S. examined the epidemiology of specific psychiatric diseases.” Dr. Weissman and many
other colleagues in collaboration examined the rates of psychiatric disorders
in 18,000 Americans. Later she compared the U.S. results to results in 9 other
countries. “Our major finding was that the majority of psychiatric disorders
began in childhood, not middle-age. These findings, I think, contributed to a
shift in psychiatric research and treatment.” Since completing large scale
surveys she has moved on to case-control and longitudinal studies of patient
populations and families. Having seen the birth of contemporary American
psychiatric epidemiology, it seems only fitting that Dr. Weissman is now
revolutionizing the field, and is among those responsible for bringing
epidemiology into the 21st century.
Transitioning From Survey Research
“I still do
epidemiology,” Dr. Weissman says, “but not much survey research.” Instead, she
is focusing on integrating epidemiology with brain imaging and genetics. The
survey research she does do is clinical, focusing on patients and families
instead of the general community. Currently, Dr. Weissman is working on a
series of studies with her colleagues at Columbia University College of
Physicians and Surgeons and the New York State Psychiatric Institute examining
the prevalence of psychiatric disorders in the primary care population. “We’re
interested in this population because, while there’ve been a number of studies
on psychiatric disorder in the primary care setting, they’ve mostly been
HMO-based, and have sampled a largely white, middle-class, working population.
The population around the Columbia hospital is predominantly composed of poor
minorities, many recent immigrants.” Dr. Weissman has finished 2 survey studies
on this population, and is now working on a third. Overall, she and her
colleagues have surveyed over 2,000 primary care patients, and they’ve found
that rates of psychiatric disorders are significantly higher in the outpatient
primary care population than has been reported in studies focusing on white,
middle-class patient populations. Dr. Weissman believes that minority
under-representation is a problem in contemporary epidemiology. African
Americans are especially wary of participating in research largely due to the
history of abuse in research. Tuskegee is well-known in the African-American
community.
Another of Dr.
Weissman’s studies based out of Columbia, focusing on the children and
grandchildren of depressed parents and grandparents, has been in the works for
20 years. They recently reported their findings: the increased risk of
depression and anxiety disorders in the offspring of depressed vs not depressed
parents continues as they move into adulthood and is transmitted to the third
generation, the grandchildren. Over 60% of the grandchildren with 2 generations
affected with depression already had a psychiatric problem. Their average age
was 12 years old.
“In these studies we’ve
been very interested in implementing modern technologies available in genetics
and neuroimaging,” Dr. Weissman says. “When we started them, back in the 70s,
genetic approaches were underdeveloped, and brain imaging applications were basically
non-existent. In our 3-generation study we’ve already performed 190 MRIs and
gathered 140 blood samples for DNA.” The results aren’t in yet, but Dr.
Weissman hopes to be done within 2 years, and further hopes that the
information will offer up valuable new insights into the genetic and
pathophysiologic mechanisms of depression in this high risk sample.
Impacting Practice
“I’ve always been
interested in how our research findings can make a positive impact on patient
care,” Dr. Weissman says. “Whenever I undertake a study, I ask: ‘what’s this
going to do for patient relief besides give us another publication?’”
“Epidemiological research can offer evidence-based answers to questions about
screening, and early detection. For example, 2 clear messages from our
3-generation study are that children of depressed mothers are more likely to be
depressed—and vice versa—and that depression in the young has serious, lasting
consequences. These two facts lead to some very evident guidelines for
screening and treatment of depression in children and adults.” One of Dr.
Weissman’s recent studies indicated that successful treatment of depression in
the parent has a positive effect on the depressive symptoms of the child.
More clinics are
instituting mandatory screening for depression and some other psychiatric
disorders in the primary care setting. If the patient is a parent of a young
child questions about the child should be part of the package. However,
according to Dr. Weissman, lack of time and money are still huge roadblocks.
She believes the will to implement increased psychiatric screening is there,
but it’s not always feasible for doctors in a primary care setting. “If you
have ten minutes to diagnose a patient with a host of physical ailments, you
don’t have much time to screen for depression,” she points out.
Advances in
understanding the risk and mechanisms of the major psychiatric disorders
require scientific collaboration among investigators with different skills,
including genetic epidemiology. These are long term studies. Our group is
involved in a multi-centered study including Columbia University, Howard University, Johns Hopkins University, University of Iowa, Stanford University, and University of Illinois. This study follows the epidemiologic findings on the high familial
nature of early onset recurrent major depression, includes some of the known
environmental factors which increase risk and is a comprehensive genetic study
which will have information on clinical characteristics, environmental risk and
DNA on 2,000 persons. The data collected without identifying information—to
preserve confidentiality—will be made available to scientific investigators
working on depression throughout the world and will become increasingly
valuable as new technologies are being developed. “A new feature of the study,”
Dr. Weissman says, “is our efforts in collaboration with Howard University and Harlem Hospital to recruit African Americans who have been largely
underrepresented in these studies.
We are very interested in recruiting persons for our genetic study of
depression. Since interviewing and blood drawing can be done in the home we
recruit from all over the country.”
|
Recruitment for the Genetic Study of Early Onset
Major Depression
Must
have:
- Major depression with onset before
age 30
- At
least 2 episodes of depression
- A
family member who also has depression beginning before age 40
- No
bipolar disorder in patient or family
Interviewing
can be done in your home and is strictly confidential.
Call toll free: 1-877-407-9529 or email
[email protected]
|
In summary, epidemiology received considerable prominence in the 1980s
as the first surveys were done to estimate the prevalence of psychiatric
disorders in the community using modern diagnostic criteria. These surveys continue
and are important in monitoring changes in rates of psychiatric disorders and
in determining the cross-cultural variations. Now, epidemiology with its
emphasis on sampling, ascertainment, research design and statistics, assessment
of diagnosis, environmental risk, and demographics has become a partner in a
host of studies involving a range of new technologies. “These are very exciting
times. Epidemiologic training is really training in basic scientific
methodology and approaches to scientific questions. It provides wide latitude
to ask a variety of questions from risk to treatment efficacy and wide
opportunities to collaborate with scientists who are highly specialized in
other approaches.”
Disclosure:
Dr. Weissman receives grant support from Eli Lilly, GlaxoSmithKline, NARSAD,
and NIMH.